目的探讨液基细胞学、液基细胞学联合核基质蛋白22(NMP 22)、膀胱肿瘤抗原(BTA)检测对膀胱癌诊断的价值。方法对收治的196例膀胱癌疑似及随访患者的尿液进行液基细胞学检查,对其中68例细胞学诊断阳性和非典型标本同时进行NMP 22、BTA检测,将结果与组织病理学诊断结果对比,评估它们对膀胱癌的诊断价值。结果液基细胞学、液基联合NMP 22、BTA和三者联合检测的敏感度分别为72.9%、83.3%、87.5%、93.8%,组间比较差异有统计学意义(P0.05);特异度分别为95.0%、80.0%、85.0%、90.0%,组间比较差异无统计学意义。结论液基细胞学联合NMP 22或(和)BTA检测可进一步提高对膀胱癌的敏感度,并无创伤性诊断方法。
Objective To explore the value of liquid-based cytology ,united urinary liquid-based cytology, unclear matrix protein 22(NMP 22) and bladder tumor antigen (BTA) in the diagnosis of the urinary carcinoma of the bladder. Methods 68 cases of positive cytology were tested the NMP-22 and BTA with comparison of histology in the 196 cases with urinary liquid-based cytology test. Results The sensitive rate in liquid-based cytology, liquid-based cytology united NMP 22, liquid-based cytology united BTA and the united three indexes were 72.9%, 83.3%, 87.5%and 93.8%accordingly and there were statistic diference(P<0.05). The specific rate in liquid-based cytology, liquid-based cytology united NMP 22 , liquid-based cytology united BTA and the united three indexes were 95.0%, 80.0%, 85.0%and 90.0%accordingly and there were no statistic diference. Conclusion Urinary liquid-based cytology united the NMP 22 and BTA test can impove the diagnosis sensitive rate of the urinary carcinoma of the bl